Context Therapeutics appoints Andy Pasternak as Chairman; Richard Berman resigns from Board

Context Therapeutics Inc.

Richard Berman resigned from Board effective Jan 12, 2025; not due to any disagreement with the Company.
Andy Pasternak appointed Chairman effective Jan 13, 2025; term through 2027 annual meeting.
Pasternak also appointed to Audit and Compensation Committees; Dr. Karen L. Smith named Compensation Committee Chair.
Pasternak granted options to purchase 20,685 shares, vesting by June 13, 2025 or 2025 annual meeting; receives $55K annual cash retainer.
Pasternak brings 25+ years pharma experience, including role in $28B Horizon-Amgen acquisition and Bain Healthcare leadership.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Richard Berman

Director

CNTX · Context Therapeutics Inc.

Effective: 2025-01-12
Successor: Andy Pasternak
Filed: January 13, 2025, 6:59 PM ET

On January 10, 2025, Richard Berman gave notice of his resignation from the Board of Directors (the “Board”) of Context Therapeutics Inc. (the "Company"), effective as of January 12, 2025.

Appointed

Andy Pasternak

Chairperson of the Board

CNTX · Context Therapeutics Inc.

Effective: 2025-01-13
Filed: January 13, 2025, 6:59 PM ET

the Board appointed Andy Pasternak as a member and Chairperson of the Board, with an initial term expiring at the Company’s 2027 annual meeting of stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Richard Berman resigned as Director at Context Therapeutics Inc..

Action: resigned
Role: Director

Exact text from the filing

On January 10, 2025, Richard Berman gave notice of his resignation from the Board of Directors (the “Board”) of Context Therapeutics Inc. (the "Company"), effective as of January 12, 2025.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Andy Pasternak was appointed as Chairperson of the Board at Context Therapeutics Inc..

Action: appointed
Role: Chairperson of the Board

Exact text from the filing

the Board appointed Andy Pasternak as a member and Chairperson of the Board, with an initial term expiring at the Company’s 2027 annual meeting of stockholders.

View on SEC.gov

Context Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001842952-25-000003

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.